Alnylam Pharmaceuticals ALNY Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's income tax?
- Alnylam Pharmaceuticals (ALNY) reported income tax of $13.31M in Q2 2026.
- How has Alnylam Pharmaceuticals's income tax changed year-over-year?
- Alnylam Pharmaceuticals's income tax decreased by 56.9% year-over-year, from $30.92M to $13.31M.
- What is the long-term trend for Alnylam Pharmaceuticals's income tax?
- Over 2 years (2022 to 2024), Alnylam Pharmaceuticals's income tax has grown at a 388.2% compound annual growth rate (CAGR), from $4.16M to -$99.22M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.